266 results about "Serum glucose" patented technology

The invention provides a fructus cannabis protein peptide capable of reducing blood sugar and regulating glycometabolism and a preparation method and application thereof, and belongs to the technical field of functional active peptides, and the preparation method comprises the following steps: performing low-temperature supersonic fluid crushing on fructus cannabis, performing enzymolysis pretreatment on the crushed fructus cannabis, adding compound protease for enzymolysis, adding PNGaseF enzyme for further enzymolysis, and performing freeze drying to obtain the fructus cannabis protein peptide capable of reducing blood sugar and regulating glycometabolism. And carrying out membrane ultrafiltration interception and enrichment on the enzymolysis supernatant, carrying out tangential flow filtration, concentrating, drying and sterilizing to obtain the fructus cannabis protein peptide. Tests prove that the novel fructus cannabis protein peptide has the following remarkable effects that the fasting blood glucose level can be remarkably reduced, and uncomfortable symptoms such as thirst, polydipsia, diuresis and weakness caused by hyperglycemia are relieved; the symptoms of glucose intolerance and insulin resistance caused by hyperglycemia can be obviously relieved, and the onset risk of type 2 diabetes mellitus is reduced; the level of fasting serum insulin and glycosylated hemoglobin can be obviously reduced, and the level of serum GLP-1 can be improved.

The present invention relates to the use of lemon exosomes in the preparation of a drug for preventing, alleviating, or treating skin ulcers. The invention creatively extracts and purifies exosomes from lemons and studies their physiological effects. Lemon exosomes can reduce the expression of inflammatory factors in macrophages, promote the healing of skin ulcers, lower blood sugar, and promote skin angiogenesis. Lemon exosomes have the advantages of good efficacy, simple raw material acquisition, and minimal toxic and side effects.

A computer implemented method matching an individual's continuous metabolite monitoring traces with another individual's continuous metabolite monitoring traces begins by identifying a concentration level of a metabolite for a subject. Dividing metabolic states into ranges of concentration levels allows for transforming a concentration level into a symbol from a set of symbols, wherein the symbol represents a category of concentration levels. The method identifies one or more strings of symbols, wherein each string of symbols represents a series of one or more symbols corresponding to a series of transformed concentration levels represented by the symbols. A computer is programmed to determine a lexical distance between a first string from the one or more strings of symbols and a second string, wherein the lexical distance corresponds to a degree of similarity between the first string and the second string. The computer provides a search result for a search query based on the determined lexical distance.

Apparatuses, systems, and methods for prosthetic valves having sensor systems are disclosed. Examples of prosthetic valves include replacement heart valves for replacing the function of a native heart valve, such as a mitral or tricuspid valve. In various embodiments, replacement heart valves are provided with sensors or markers for assisting with proper placement and / or securement in the body. A replacement heart valve may include anchors for securing the replacement heart valve to native leaflets, wherein sensors and / or markers provide feedback to the physician for confirming proper placement of the anchors during the implantation procedure. Sensors may also be used to assess the function of the prosthetic valve after deployment. Sensors may also be used to monitor blood pressure, temperature, oxygen, insulin, cholesterol, and / or glucose to assess overall patient health.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses a phloretin derivative and application of the phloretin derivative in preparation of a medicine for treating diabetes and complications thereof, and relates to the technical field of small molecule medicines. The structure of the phloretin derivative is shown in the specification. Compared with existing phloretin (unmodified) and a clinically common alpha-glucosidase inhibitor (such as acarbose), the phloretin derivative obtained through structural modification can more efficiently inhibit the activity of alpha-glucosidase, further more effectively delays decomposition and absorption of starch substances, has a better stable regulation effect on postprandial blood sugar, and can be used for preparing the phloretin derivative. The core problem that the existing phloretin inhibitory activity is insufficient is solved.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention provides an application of cichorium glandulosum polysaccharide in preparation, basic characterization and type 2 diabetes mellitus relieving medicines, and belongs to the technical field of medicines. Animal experiment results show that after the cichorium glandulosum polysaccharide is applied to type 2 diabetic mice, serum biochemical indexes can be adjusted, the blood sugar level can be reduced, organ injuries can be protected or repaired, and PI3K / AKT / mTOR signal channel related protein expression in the main glycometabolism target organ liver can be adjusted. Therefore, the prepared cichorium glandulosum polysaccharide can be used as a medicine for relieving type 2 diabetes mellitus.

The invention provides a preparation method of probiotic fermented polygonatum sibiricum polysaccharide, and belongs to the field of traditional Chinese medicinal material processing. The preparation method comprises the following steps: (1) adding cellulase and pectinase into polygonatum kingianum, carrying out water extraction, carrying out enzyme deactivation after water extraction, and carrying out suction filtration to obtain filtrate; (2) preparing bacillus DU-106 and lactobacillus plantarum nbk-MA2 into bacterial powder, and adding water to obtain bacterial liquid; mixing the bacterial liquid with the filtrate, fermenting, performing suction filtration, and centrifuging to obtain supernate; performing alcohol precipitation to remove protein; carrying out ethanol precipitation by using absolute ethyl alcohol again, collecting the precipitate after centrifuging, and carrying out redissolution, dialysis and freeze-drying to obtain fermentation modified crude polysaccharide; and (3) purifying the fermented and modified crude polysaccharide to obtain a purified polysaccharide component. The obtained probiotic fermented polygonatum sibiricum polysaccharide has the effect of losing weight, and can obviously improve the obesity characteristics of mice, specifically, reducing body weight, reducing fat, reducing serum liver lipid level, relieving serum liver inflammation of the mice, weakening blood glucose insulin sensitivity, repairing liver injury and the like.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention relates to a mitochondrial uncoupling inhibitor sustained-release nanodot, a preparation method thereof and application of the nanodot in type 2 diabetes mellitus, and belongs to the technical field of nano-drugs. According to the preparation method disclosed by the invention, glycine and genipin are subjected to Schiff reaction to prepare the slow-release nanodot, and the slow-release nanodot is of a monodisperse spherical structure, has surface negative charges, and can slowly release genipin under physiological conditions, so that the mitochondrial protection effect of the genipin is fully exerted. The mitochondrial uncoupling inhibitor slow-release nanodot prepared by the invention can obviously improve the mitochondrial membrane potential, increase the cell ATP content, effectively inhibit mtDNA release under the stimulation of IL-1beta and palmitic acid, effectively inhibit STING inflammation pathway activation under the stimulation of IL-1beta and PA, obviously reduce pancreatic beta cell apoptosis, obviously relieve endoplasmic reticulum stress, and can be used for preparing the mitochondrial uncoupling inhibitor slow-release nanodot. The T2DM mouse blood sugar is obviously reduced, the glucose tolerance dose and the insulin sensitivity are improved, and good biocompatibility is achieved.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention provides a coin-sized, fully integrated and wearable continuous blood glucose monitoring (CGM) system in combination with frontier technologies in crossing fields of biosensors, minimally invasive tools, hydrogels and the like. The invention comprises the following three main parts: 1) an emerging biochemical amplifier, namely an organic electrochemical transistor (OECT), for improving the sensitivity and exceeding the traditional electrochemical sensor; 2) a microneedle array for sampling interstitial fluid (ISF), which reduces pain in the skin penetration process; and 3) a tough and viscous enzyme hydrogel film which can improve the reliability of glucose sensing on the skin. Different from a traditional CGM, the CGM (OECT-CGM) provided by the invention has high anti-noise capability, adjustable sensitivity and current regeneration capability due to the adoption of the OECT amplifier, so that long-term stable glucose sensing can be realized within a specific clinical range (1-20mM). The CGM provided by the invention can provide high and adjustable sensitivity, minimally invasive property and better wearable property at the same time, and also paves a way for developing the next generation of CGM.

This invention provides a coin-sized, fully integrated and wearable continuous glucose monitoring system (CGMs) via combining cutting-edge technologies from the intersecting fields of biosensors, minimally invasive tools, and hydrogels. The invention includes three major parts: 1) an emerging biochemical amplifier, the organic electrochemical transistor (OECT), to improve sensitivity beyond traditional electrochemical modules; 2) a microneedle array for interstitial-fluid (ISF) sampling with reduced pain during skin penetration; and 3) a tough, adhesive enzymatic-hydrogel-membrane to enhance reliability of glucose sensing on skin. Unlike conventional CGMs, the employed OECT amplifier empowers the CGM (OECT-CGMs) with a high anti-noise ability, an on-demand-tunable sensitivity and current regeneration ability, enabling long-term stable glucose sensing within specific clinical ranges (1˜20 mM). This work paves the way for the development of next-generation CGMs that can simultaneously deliver high and adjustable sensitivity, minimal invasiveness, and improved wearability.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The invention provides a sugar fat disease death risk prediction method and system based on NHANES data, and the method comprises the steps: obtaining the fasting blood glucose FPG and glycosylated hemoglobin HbA1c clinical detection data of a sugar fat disease patient, and calculating an SHR value through a formula; based on the data of the NHANES database, SHR total cause bilateral critical values of total cause death rate and cardiovascular death rate, SHR cardiovascular bilateral critical values and SHR cancer unilateral critical values of cancer death rate are obtained; and comparing the SHR value with an SHR total cause double-side critical value, an SHR cardiovascular double-side critical value and an SHR cancer single-side critical value of the cancer death rate, and carrying out risk layering and evaluation. The biochemical aging acceleration index has a prediction effect on the diabetes death risk, and KDMAgeAccel significantly intermediates the death risk caused by SHR.

The application discloses a glucagon peptide-1 and glucagon receptor dual-agonistic polypeptide and application thereof, and the polypeptide structure is shown in the following general formula (I). The dual-agonistic polypeptide has dual-agonistic activity on human GLP-1 and glucagon receptors. The GLP-1 / glucagon receptor dual-agonistic polypeptide can effectively reduce blood sugar and weight, and has obvious lipid-regulating effect. The GLP-1 / glucagon receptor dual-agonistic polypeptide is stable in vivo, and is suitable to be used as an active component of drugs for diabetes, obesity, hyperlipidemia and the like.

The application discloses application of Xintong preparation in preparation of a medicine for treating diabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The Xintong preparation is prepared from 13 raw medicinal materials of Huangqi, Gegen, Danshen, Dangshen, Maidong, Heshouwu, Yinyanghuo, Dangui, Zaokesheng, Haizao, Kelp, Muli and Zhishi, has the effects of benefiting qi and activating blood, reducing phlegm and dredging collaterals. Pharmacodynamic experiments show that the Xintong preparation has the effect of reducing blood sugar, can effectively improve the physical conditions of polydipsia, polyphagia, polyuria and emaciation and lack of strength of an animal model of diabetes, significantly reduces the fasting blood sugar and serum insulin level, improves the oral glucose tolerance, has a definite treatment effect on type II diabetes, and expands the clinical application range of the Xintong preparation, and has a wide market application prospect.

The invention relates to the technical field of biological medicines, in particular to application of N-acetylcysteine in preparation of a medicine for improving intestinal injuries caused by diabetic hyperthyroidism complicated diseases, and the N-acetylcysteine is used for preparing the medicine for improving the intestinal injuries caused by the diabetic hyperthyroidism complicated diseases. The traditional Chinese medicine composition can effectively relieve abnormal blood glucose rise of diabetic hyperthyroidism complications, and improve excessive ingestion and drinking conditions and intestinal injury.

The present invention discloses applications and methods of Leuconostoc mesenteroides, relating to the field of microbial technology. Leuconostoc mesenteroides can be used to prepare phytic acid and improve non-alcoholic fatty liver disease, increased liver weight, elevated blood lipids, elevated blood sugar, elevated serum lipopolysaccharide levels, elevated serum insulin levels, inflammatory responses, and elevated triglyceride levels in the liver caused by a high-fat, high-sugar diet, and inhibit the release of the pro-inflammatory cytokine lipopolysaccharide.

The present invention discloses the application of Alternariol in the preparation of diabetes prevention and treatment drugs, which belongs to the field of medical technology. The present invention first screens out the compound Alternariol through in vitro DYRK1A kinase activity experiment, and its IC 50 The value was 20μM. Then, through INS-1 cell proliferation model experiments, it was found that the compound Alternariol can promote INS-1 cell proliferation and promote insulin secretion by pancreatic islet cells. Even at very low concentrations, such as 300nmol, it can significantly promote INS-1 cell proliferation. Finally, through mouse diabetes model experiments, it was further verified that the compound Alternariol can indeed control blood sugar in T1D mice and promote pancreatic proliferation in mice, while also having no toxic effects on the mouse body. This invention has extraordinary significance for T1B diabetes with impaired pancreatic cell function.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

How to treat injuries or conditions associated with CNS edema [Solution] This technology relates to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the method includes reducing late neurological exacerbations or preventing death, reducing midline deviation of the brain, reducing the degree of functional impairment in subjects, neutralizing blood glucose levels in subjects receiving SUR1-TRPM4 channel inhibitors, preventing cerebral swelling, treating injuries or conditions associated with CNS edema while monitoring liver enzyme activity, or treating injuries or conditions associated with CNS edema while monitoring cardiac activity.

The present invention discloses a 1,2,4-triazole-phenylacetamide α-glucosidase inhibitor and its preparation method and application. The chemical structure of this type of α-glucosidase inhibitor is shown in formula (I): #imgabs0# The 1,2,4-triazole-phenylacetamide α-glucosidase inhibitor disclosed by the present invention not only has good effects of inhibiting the activity of α-glucosidase and reducing postprandial blood sugar, but can be used as a lead compound for novel anti-diabetic research; it also has low toxicity to normal human cells and high safety; and the preparation method of the 1,2,4-triazole-phenylacetamide compound disclosed by the present invention is simple, the synthetic route is short, it is easy to prepare in large quantities, the price is low, and it is suitable for market promotion and application.

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.